Q3 2024 Earnings Forecast for Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Issued By HC Wainwright

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Analysts at HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for Dianthus Therapeutics in a report issued on Monday, August 12th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.53) per share for the quarter, down from their previous estimate of ($0.33). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2024 earnings at ($0.73) EPS, FY2024 earnings at ($2.33) EPS, Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.36) EPS, FY2026 earnings at ($4.49) EPS, FY2027 earnings at ($4.88) EPS and FY2028 earnings at ($3.72) EPS.

A number of other equities research analysts have also issued reports on the stock. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating for the company. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Robert W. Baird initiated coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 price target for the company. Finally, Wedbush dropped their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Buy” and an average target price of $44.71.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $29.81 on Wednesday. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77. The company has a market capitalization of $874.89 million, a PE ratio of -5.11 and a beta of 1.89. The company’s 50 day moving average price is $26.82 and its 200 day moving average price is $25.27.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The firm had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at about $25,000. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $112,000. The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $236,000. WINTON GROUP Ltd acquired a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $265,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $334,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.